Bearing in mind the FP-ENAS task force and research expertise, for effective governance, the Unit is organized in two Research Groups which have their own facilities, specialized laboratories and also use the existing general research laboratories of the UFP: 3ERL – Energy, Environment and Environmental & Public Health Research Laboratories, with regard to Energy and Environmental sciences including their impact in public health and CEBIMED – Biomedical Research Centre, concerning Health Sciences.

3ERL is a multidisciplinary research group focused in two distinct but complementary thematic domains: (i) Fossil energies: clean technologies for a rational exploitation and utilization; and (ii) Environment, & Environmental and Public Health.

3ERL team members are building knowledge in (i) reservoir modelling, (ii) source rock geochemical modelling, (iii) GHG emissions and CO2 geological sequestration, (iv) energy problems, (v) ecology of freshwater ecosystems, (vi) atmospheric pollutants exposure modelling, (vii) water resources management, (viii) water quality and sediment transport.

CEBIMED is a multidisciplinary research group focused in three distinct but complementary thematic domains: (i) Microbiology, Immunology and Genetics; (ii) Toxicology and Pharmacology; and (iii) Chemistry and Pharmacy.

The scientific achievements of the CEBIMED researchers are related to the development of knowledge on a wide range of disciplines highlighting the team expertise in:

(i) biotechnology and health,
(ii) computational biochemistry (e.g. bioinformatics, systems biology, computational pharmacology, metabolism, genetics, statistics);
(iii) medical biology (e.g. convergence with the pathophysiology of clinical medicine as diagnostic tools),
(iv) molecular biology and immunology (e.g. molecular interactions inherent to chronic diseases, protein biosynthesis, DNA, RNA, aptamers, immunoglobulin),
(v) self-medication and pharmacological addiction (e.g. processes of pharmacotherapy, monitoring, pharmacogenetics and pharmacogenomics, adverse drug reactions, drug interactions, pharmacotoxicology, drug dependence and report abuse, treatment of poisoning), and
(vi) new drugs and new drug delivery systems in the pharmaceutical industry, research of new biologically active molecules.